JEV Human T cell

Published: 3 December 2020| Version 1 | DOI: 10.17632/2g9jv6bzx5.1
Vijaya Satchidanandam


JEV exposed human volunteers comprising healthy contacts and recovered JEV patients were recruited for this study. Individuals who received the live attenuated JE vaccine SA14-14-2 were also included. Blood drawn was stimulated with capsid, envelope and NS3 proteins of JEV, PS cells uninfected and infected with JEV along with cells alone controls. The FACS antibody panel consisting of anti-CD3-APC-H7 (clone SK7), anti-CD8-PerCP (clone SK1), anti-IFN--PECy7 (clone B27), anti-IL-2-FITC (MQ1-17H12), anti-TNFα-APC (6401-1111) and anti-MIP-1β-PE (11A3), from BD Pharmingen, San Diego, CA.